FDA awards Commissioner's National Priority Vouchers to three psychedelic products

President Trump on April 18 issued an Executive Order directing the U.S. Department of Health and Human Services to accelerate access to treatments for patients with serious mental illness, including devastating, complex, and treatment-resistant conditions.

Building on this directive, the U.S. Food and Drug Administration today announced a series of regulatory actions to support the development of serotonin-2A agonists and related products, a class of perception-altering psychedelic medications.

The FDA is issuing Commissioner's National Priority Vouchers to three companies studying:

• Psilocybin for treatment-resistant depression (Compass Pathways).
• Psilocybin for major depressive disorder (Usona Institute).
• Methylone for post-traumatic stress disorder (transcend therapeutics).

‍

Source: Press Release